A new treatment for multiple sclerosis (MS) has enabled some patients to walk again by “rebooting” their immune systems.
As part of a clinical trial at Sheffield’s Royal Hallamshire Hospital involving around 20 patients, scientists used stem cells to carry out a bone marrow transplant.
The method known as an autologous haematopoietic stem cell transplant (HSCT) works by using chemotherapy to destroy the area of the immune system which causes MS.
The trial has been documented as part of a BBC Panorama programme.
The trial has been so effective for some patients that they have been able to walk once more.
Professor John Snowden, consultant haematologist at Royal Hallamshire Hospital, said that the patient’s immune systems were “reset or rebooted “back to a time point before it caused MS.
“It’s clear we have made a big impact on patients’ lives, which is gratifying.”
Professor Basil Sharrack of the Royal Hallamshire described the treatment as a “major achievement”.
MS affects the central nervous system, and is generally diagnosed when a person is in their 20s or 30s.
More than 100,000 people in the UK are currently living with the incurable neurological disease.
Amy Bowen, Director of Service Development at the MS Trust said that the treatment is “very powerful” but said it has “significant risks as well as potential benefits”.
“It’s a long way from being a routine treatment for MS,” said. “We still need more clinical trials to understand who is most likely to benefit from treatment, to develop safer treatment procedures and understand what the long-term effects of treatment might be.”
Dr Emma Gray, head of clinical trials at UK’s MS Society said: “Ongoing research suggests stem cell treatments such as HSCT could offer hope, and it’s clear that, in the cases highlighted by Panorama, they’ve had a life-changing impact.
“However, trials have found that, while HSCT may be able to stabilise or improve disability in some people with MS, it may not be effective for all types of the condition.
“We want people to be aware that HSCT is an aggressive treatment that comes with significant risks. It needs to be carried out at an accredited centre or as part of a clinical trial.
“The MS Society has recently funded a study looking into the impact of HSCT on the immune system and we’d like to see larger trials in this area. They would help us learn more about the safety and long term effectiveness of the treatment and who could benefit from it.”
To read the full article click here.
BSc (Hons) Microbiology
Biovault Family CEO, Kate Sneddon, joined Biovault in July 2009 and became Chief Executive Officer in 2016. As health industry professional her experience includes working as a microbiologist and leader at GSK for over 10 years. Her expertise in cord blood banking has been recognised in her awards, features in Parliamentary Review and Parents Guide to Cord Blood, as well as contributions to research with UCL and others.